GlaxoSmithKline’s HIV treatment is now coming to England and Wales after a year of use in the US. This treatment will revolutionise the lives of people living with HIV because they can receive jabs every two months rather than taking pills orally every day.

In December of last year, the drug known as Vocabria was signed off by the EU. The same product was accepted by the FDA (Food and Drug Administration) in January to be used alongside Edurant in the UK.

Having a grounding on where a pharmaceutical product lies on an integrated delivery network is of equal importance to concentrating on payers and pharmacy benefit managers. You can use MMIT’s PULSE Analytics solution to assist in estimating pathway placement and find ways to increase availability of your product.

On the back of research testing safety and operation of Cabenuva compared to a standard treatment, the HIV treatment received approval. The research proved that injecting HIV patients once monthly had similar results to taking treatment pills every day. After this, another study was conducted, concluding that injections every two months has the same effects as every month.

ViiV’s senior global medical director, Nneka Nwokolo, said “We are committed to listening to people living with HIV to understand their priorities for treatment options and to push boundaries to develop therapies that meet their needs,”

In a recent study, it was discovered that 60% of people living with HIV are scared that their medical issue will be revealed without their approval, and 45% said that they had been seen taking their drugs and therefore were put in a position where they had to divulge their condition.

“We still have a long way to go in educating around HIV, but today’s announcement demonstrates how far we’ve come since the 1980s epidemic,” Garry Brough of Positively UK said in a statement. “Having to take tablets every day can be physically, emotionally and socially burdensome for some people. This decision reflects the rightful need for people living with HIV to have the freedom to manage their HIV in a way that works best for them, helping them to live their life to the full.”

A treatment to help prevent HIV (Cabenuva ) is currently in the works and being produced by GSK.